Caterina Mancarella

Biologist
Experimental Oncology
Orthopaedic Rizzoli Institute
Italy

Academician Oncology
Biography

From January 2016: Post-Doc AIRC/FIRC triennial fellowship at the Laboratory of Experimental Oncology, Rizzoli Orthopedic Institute Rizzoli. Project: Dissecting thje role of IGF2BP3 in the malignancy of Ewing sarcoma. From May to December 2015: Post-Doc at the Experimental Oncology Laboratory, Rizzoli Orthopedic Institute. July 2012 - December 2012: abroad research experience at Molecular Biology Laboratory, Instituto Valenciano de Oncologia, Valencia (Spain). Project: IGF system, CD99 molecule, tumor-specific chromosomal translocations: evaluation of their prognostic value in prostate cancer. January 2012 - current: PhD student in Oncology and Experimental Pathology, University of Bologna at Experimental Oncology Laboratory, Orthopedic Institute Rizzoli, Bologna. Project: IGF system, CD99 molecule, tumor-specific chromosomal translocations: evaluation of their prognostic value in prostate cancer and Ewing sarcoma. Tutor: prof. Pietro Ruggieri. August 2011 - current: Fellowship in oncology at Experimental Oncology Laboratory, Orthopedic Institute Rizzoli, Bologna. April - June 2011: Frequent visitor at Experimental Oncology Laboratory, Orthopedic Institute Rizzoli, Bologna. Project: Molecular mechanisms at the basis of resistance to new insulin-like growth factor 1 receptor targeted therapy. February 2010 - March 2011: Internal student at Experimental Oncology Laboratory, Orthopedic Institute Rizzoli, Bologna . Project: Molecular mechanisms at the basis of resistance to new insulin-like growth factor 1 receptor targeted therapy. April 2008 - June 2008: Internal student at Biochemistry Laboratory at Faculty of Biology, University of Bologna. Project: Characterization of fibroblasts mitochondrial functions in monkeys affected by optic neuropathy.

Research Intrest

Molecular mechanisms at the basis of resistance to new insulin-like growth factor 1 receptor targeted therapy. Study of RNA-binding proteins in Ewing sarcoma

List of Publications
Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, Di Giandomenico S, Ordóñez JL, Sevillano V, Malaguarnera R, Picci P. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents. Clinical Cancer Research. 2015 Mar 15;21(6):1373-82.
Casanova-Salas I, Masiá E, Armiñán A, Calatrava A, Mancarella C, Rubio-Briones J, Scotlandi K, Vicent MJ, López-Guerrero JA. MiR-187 targets the androgen-regulated gene ALDH1A3 in prostate cancer. PloS one. 2015 May 13;10(5):e0125576.
Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A, Rubio L, Ramírez-Backhaus M, Armiñán A, Domínguez-Escrig J. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. The Journal of urology. 2014 Jul 31;192(1):252-9.